Changes of c-fos and c-jun mRNA Expression in Angiotensin Ⅱ-induced Cardiomyocyte Hypertrophy and Effects of Sodium Tanshinone ⅡA Sulfonate

The changes of proto-oncogene c-fos and c-jun mRNA expression in angiotensin Ⅱ （AngⅡ）-induced hypertrophy and effects of sodium tanshinone ⅡA sulfonate （STS） in the primary culture of neonatal rat cardiomyocytes were investigated. Twelve neonatal clean grade Wistar rats were selected. The cardiomyocytes were isolated, cultured and divided according to different treatments in the medium. The cardiomyocyte size was determined by phase contrast microscope, and the rate of protein synthesis was measured by [3H]-Leucine incorporation. The c-fos and c-jun mRNA expression in cardiomyocytes was detected by reverse transcription polymerase chain reaction （RT-PCR）. It was found after cardiomyocytes were treated with AngⅡ for 30 min, the c-fos and c-jun mRNA expression in cardiomyocytes was increased significantly （P〈0.01）. After treatment with AngⅡ for 24 h, the rate of protein synthesis in AngⅡ group was significantly increased as compared with control group （P〈0.01）. After treatment with AngⅡ for 7 days, the size of cardiomyocytes in AngⅡ group was increased obviously as compared with control group （P〈0.05）. After pretreatment with STS or Valsartan before AngⅡ treatment, both of them could inhibit the above effects of AngⅡ （P〈0.05 or P〈0.01）. It was suggested that STS could ameliorate AngⅡ-induced cardiomyocyte hy- pertrophy by inhibiting c-fos and c-jun mRNA expression and reducing protein synthesis rate of cardiomyocytes.

Protective Effect and Mechanism of Sodium Tanshinone ⅡA Sulfonate on Microcirculatory Disturbance of Small Intestine in Rats with Sepsis

To explore the protective effect of sodium tanshinone ⅡA sulfonate（STS） on microcirculatory disturbance of small intestine in rats with sepsis,and the possible mechanism,a rat model of sepsis was induced by cecal ligation and puncture（CLP）.Rats were randomly divided into 3 groups：sham operated group（S）,sepsis group（CLP） and STS treatment group（STS）.STS（1 mg/kg） was slowly injected through the right external jugular vein after CLP.The histopathologic changes in the intestinal tissue and changes of mesenteric microcirculation were observed.The levels of tumor necrosis factor-α（TNF-α） in the intestinal tissue were determined by using enzyme-linked immunoabsorbent assay（ELISA）.The expression of intercellular adhesion molecule-1（ICAM-1） in the intestinal tissue was detected by using immunohistochemisty and Western blot,that of nuclear factor κB（NF-κB） and tissue factor（TF） by using Western blot,and the levels of NF-κB mRNA expression by using RT-PCR respectively.The microcirculatory disturbance of the intestine was aggravated after CLP.The injury of the intestinal tissues was obviously aggravated in CLP group as compared with S group.The expression levels of NF-κB p65,ICAM-1,TF and TNF-α were upregulaed after CLP（P0.01）.STS post-treatment could ameliorate the microcirculatory disturbance,attenuate the injury of the intestinal tissues induced by CLP,and decrease the levels of NF-κB,ICAM-1,TF and TNF-α（P0.01）.It is suggested that STS can ameliorate the microcirculatory disturbance of the small intestine in rats with sepsis,and the mechanism may be associated with the inhibition of inflammatory responses and amelioration of coagulation abnormality.

Sodium tanshinone IIA sulfonate attenuates cardiac dysfunction and improves survival of rats with cecal ligation and puncture-induced sepsis

Cardiac dysfunction, a common consequence of sepsis, is the major contribution to morbidity and mortality in patients. Sodium tanshinone IIA sulfonate(STS) is a water-soluble derivative of Tanshinone IIA(TA), a main active component of Salvia miltiorrhiza Bunge, which has been widely used in China for the treatment of cardiovascular and cerebral system diseases. In the present study, the effect of STS on sepsis-induced cardiac dysfunction was investigated and its effect on survival rate of rats with sepsis was also evaluated. STS treatment could significantly decrease the serum levels of C-reactive protein(CRP), procalcitonin(PCT), cardiac troponin Ⅰ(cTn-Ⅰ), cardiac troponin T(cTn-T), and brain natriuretic peptide(BNP) in cecal ligation and puncture(CLP)-induced) septic rats and improve left ventricular function, particularly at 48 and 72 h after CLP. As the pathogenesis of septic myocardial dysfunction is attributable to dysregulated systemic inflammatory responses, several key cytokines, including tumor necrosis factor-α(TNF-α), interleukin-1β(IL-1β), interleukin-6(IL-6), interleukin-10(IL-10) and high mobility group protein B1(HMGB1), were detected to reveal the possible mechanism of attenuation of septic myocardial dysfunction after being treated by STS. Our study showed that STS, especially at a high dose(15 mg×kg–1), could efficiently suppress inflammatory responses in myocardium and reduce myocardial necrosis through markedly reducing production of myocardial TNF-α, IL-6 and HMGB1. STS significantly improved the 18-day survival rate of rats with sepsis from 0% to 30%(P < 0.05). Therefore, STS could suppress inflammatory responses and improve left ventricular function in rats with sepsis, suggesting that it may be developed for the treatment of sepsis.

Lower clearance of sodium tanshinone IIA sulfonate in coronary heart disease patients and the effect of total bilirubin: a population pharmacokinetics analysis

This study developed a population pharmacokinetic model for sodium tanshinone IIA sulfonate(STS) in healthy volunteers and coronary heart disease(CHD) patients in order to identify significant covariates for the pharmacokinetics of STS. Blood samples were obtained by intense sampling approach from 10 healthy volunteers and sparse sampling from 25 CHD patients, and a population pharmacokinetic analysis was performed by nonlinear mixed-effect modeling. The final model was evaluated by bootstrap and visual predictive check. A total of 230 plasma concentrations were included, 137 from healthy volunteers and 93 from CHD patients. It was a two-compartment model with first-order elimination. The typical value of the apparent clearance(CL) of STS in CHD patients with total bilirubin(TBIL) level of 10 μmol×L^(–1) was 48.7 L×h^(–1) with inter individual variability of 27.4%, whereas that in healthy volunteers with the same TBIL level was 63.1 L×h^(–1). Residual variability was described by a proportional error model and estimated at 5.2%. The CL of STS in CHD patients was lower than that in healthy volunteers and decreased when TBIL levels increased. The bootstrap and visual predictive check confirmed the stability and validity of the final model. These results suggested that STS dosage adjustment might be considered based on TBIL levels in CHD patients.

Two-step continuous flow process of sodium tanshinone ⅡA sulfonate using a 3D circular cyclone-type microreactor

A sustainable and practical process is presented for the direct synthesis of sodium tanshinone IIA sulfonate(STS).Our approach was inspired by the well-established and industrially applied batch synthetic route for STS production.We constructed a telescoped two-step continuous flow platform.This involved a continuous tanshinone IIA sulfonation and in-line salt formation.For the setup,we constructed a 3D circular cyclone-type microreactor using femtosecond laser micromachining.Compared to the 68%yield for 2 h in batch,the two-step continuous flow had an STS yield of 90%,achieved for a total residence time of<3.0 min under optimal conditions.The proposed continuous flow method vastly simplified the operation and improved procedural safety,while significantly reducing the required acid content and wastewater production.

Protective Effect of Sodium Tanshinone ⅡA Sulfonate on Injury of Small Intestine in Rats with Sepsis and Its Mechanism

Objective： To explore the protective effect of sodium tanshinone ⅡA sulfonate （STS） on small intestine injury in rats with sepsis and its possible mechanism. Methods： According to a random number table, 24 Tats were randomly divided into 3 groups： sham operation group （sham group）, sepsis model group （model group） and STS treatment group （STS group）, with 8 Tats in each group. A rat model of sepsis was induced by cecal ligation and puncture （CLP） for 5 h. STS （1 mg/kg） was slowly injected through the right external jugular vein after CLP. The histopathologic changes in the intestine tissue were observed under a light microscope, and the intestinal epithelial cell apoptosis was evaluated by terminal deoxynucleoddyl transferase （TdT）-mediated dUTP nick-end labeling （TUNEL） method. The expressions of Bcl-2, Bax and nuclear factor κB （NF- κ B） p65 in the intestinal tissue was determined by Western blot. The levels of tumor necrosis factor α （TNF-α） and interleukin 6 （IL-6） in the intestinal tissue were determined using enzyme-linked immuno-sorbent assay （ELISA）. Results： Obvious injuries were observed in the intestinal tissue in the CLP group compared with the sham group. The expression of NF- K B p65 and the levels of TNF- α and IL-6 were up-regulated after CLP, the apoptosis of intestinal epithelial cells was increased after CLP, and the ratio of Bcl-2 to Bax was decreased. STS post- treatment could attenuate the injury on the intestinal tissue induced by CLP, decrease the apoptosis of intestinal epithelial cells and the levels of NF- κ B p65, TNF-α and IL-6, and increase the ratio of Bcl-2 to Bax. Conclusion： STS can protect the small intestine in rats with sepsis, and the mechanism may be associated with the inhibition of intestinal epithelial apoptosis and the reduction of activation of inflammatory cytokines.

Sodium tanshinone ⅡA sulfonate prevents radiation-induced damage in primary rat cardiac fibroblasts

This study investigated the effects of X-ray irradiation on primary rat cardiac fibroblasts(CFs) and its potential mechanism, as well as whether sodium tanshinone ⅡA sulfonate(STS) has protective effect on CFs and its possible mechanism. Our data demonstrated that X-rays inhibited cell growth and increased oxidative stress in CFs, and STS mitigated X-ray-induced injury. Enzyme-linked immuno-sorbent assay showed that X-rays increased the levels of secreted angiotensin Ⅱ(Ang Ⅱ) and brain natriuretic peptide(BNP). STS inhibited the X-ray-induced increases in Ang Ⅱ and BNP release. Apoptosis and cell cycle of CFs were analyzed using flow cytometry. X-rays induced apoptosis in CFs, whereas STS inhibited apoptosis in CFs after X-ray irradiation. X-rays induced S-phase cell cycle arrest in CFs, which could be reversed by STS. X-rays increased the expression of phosphorylated-P38/P38,cleaved caspase-3 and caspase-3 as well as decreased the expression of phosphorylated extracellular signal-regulated kinase 1/2(ERK1/2)/ERK 1/2 and B cell lymphoma 2(Bcl-2)/Bcl-2 associated X protein(BAX) in CFs, as shown by Western blotting. STS mitigated the X-ray radiation-induced expression changes of these proteins. In conclusion, our results demonstrated that STS may potentially be developed as a medical countermeasure to mitigate radiation-induced cardiac damage.

Effect of Sodium Tanshinone ⅡA Sulfonate on Phosphorylation of Extracellular Signal-regulated Kinasel/2 in Angiotensin Ⅱ-induced Hypertrophy of Myocardial Cells

Objective： To observe the effects of sodium tanshinone ⅡA sulfonate （STS） on angiotensin Ⅱ （Ang Ⅱ）-induced hypertrophy of myocardial cells through the expression of phosphorylated extracellular signal-regulated kinase （p-ERK1/2）. Methods： In the primary culture of neonatal rat myocardial cells, the total protein content in myocardial cells was determined by coomassie brilliant blue and the protein synthesis rate was measured by [3H]-Leucine incorporation as indexes for hypertrophy of myocardial cells. The expression of p-ERK1/2 was determined using Western blot and immunofluorescence labeling. Results： （1） The total protein and protein synthesis rate increased significantly in contrast to the control group after the myocardial cells were stimulated by Ang Ⅱ （1 μ mol/L） for 24 h; STS markedly inhibited the increment of the total protein level induced by Ang Ⅱ and the syntheses of protein. （2） After pretreatment of myocardial cells with Ang Ⅱ （1 μmol/L） for 5 min, the p-ERK1/2 protein expression was increased, with the most obvious effect shown at about 10 min; pretreatment of myocardial cells with STS at different doses （2, 10, 50μmol/L） for 30 min resulted in obvious inhibition of the expression of p-ERK1/2 stimulated by Ang Ⅱ in a dose-dependent manner. （3） After the myocardial cells were stimulated by AngⅡ （1 μ mol/L）, the immunofluorescence of ERK1/2 rapidly appeared in the nucleus. The activation and translocation process of ERK1/2 induced by Ang Ⅱ was blocked distinctly by STS. （Conclusion： STS inhibited the myocardial cell hypertrophy induced by Ang Ⅱ, and the mechanism may be associated with the inhibition of p-ERK1/2 expression.

Effect of Sodium Tanshinone ⅡA Sulfonate on Cardiac Myocyte Hypertrophy and Its Underlying Mechanism

Objective： To investigate the effects of sodium tanshinone Ⅱ A sulfonate （STS） on the hypertrophy induced by angiotensin Ⅱ（Ang Ⅱ） in primary cultured neonatal rat cardiac myocytes. Methods： The effect of STS on cytotoxicity was evaluated using the 3-（4,5-dimethylthiazol-2-yl）-3,5- phenytetrazoliumromide （MTT） assay. As indexes for cardiocyte hypertrophy, cell size was determined by phase contrast microscopy and protein synthesis rate was measured by 3H-leucine incorporation. The proto-oncogene c-fos mRNA expression of cardiocytes was assessed using reverse transcription polymerase chain reaction （RT-PCR）. Results： STS could inhibit cardiocyte hypertrophy, increase the protein synthesis rate and enhance proto-oncogene c-fos mRNA expression in cardiocytes induced by Ang Ⅱ（P〈0.01）, with an effect similar to that of Valsartan, the Ang Ⅱ receptor antagonist. Conclusion： STS can prevent the hypertrophy of cardiac myocytes induced by Ang Ⅱ, which may be related to its inhibition of the expression of proto-oncogene c-fos mRNA.

Sodium Tanshinone Ⅱ A sulfonate for acute myocardial infarction:a systematic review and Meta-analysis

OBJECTIVE: To investigate the efficacy and safety of Sodium tanshinone ⅡA sulfonate(STS) plus the conventional treatment on acute myocardial infarction(AMI) patients.METHODS: We searched several electrical databases and hand searched several Chinese medical journals up to January 2019. Randomized controlled trials(RCTs) comparing STS plus conventional treatment with conventional treatment were retrieved.Study screening, data extraction, quality assessment, and data analysis were conducted in accordance with the Cochrane standards.RESULTS: Sixteen trials involving 1383 people were included. The Meta-analysis showed STS combined with conventional treatment was a better treatment option than conventional treatment alone in reducing the risk of mortality, heart failure, arrhythmia and shock. In addition, STS was associated with improvement in left ventricular ejection fraction(LVEF) and left ventricular end diastolic dimension(LVEDD). No significant difference of STS was found on recurrent angina and recurrent AMI. However,the safety of STS remained uncertain for limited data.CONCLUSION: Compared with conventional treatment alone, STS combined with conventional treatment may provide more benefits for patients with AMI. Due to the fact that the overall quality of all included trials is generally low, further large-scale high quality trials are warranted.

Sodium Tanshinone Ⅱ A Sulfonate Injection as Adjuvant Treatment for Unstable Angina Pectoris: A Meta-Analysis of 17 Randomized Controlled Trials

Objective： To systematically evaluate the effectiveness and safety of Sodium Tanshinone ⅡA Sulfonate Injection（STS） as one adjuvant therapy for treating unstable angina pectoris（UAP）. Methods： Randomized controlled trials（RCTs） of UAP treated by STS were searched in the China National Knowledge Infrastructure Database（CNKI）, VIP Database for Chinese Technical Periodicals（VIP）, Wanfang Database, the Chinese Biomedical Literature Database（CBM）, Web of Science, the Cochrane Library, Embase, and Pub Med, which from inception to January, 2016. The Cochrane Risk Assessment Tool was used to evaluate the methodological quality of the RCTs. The Review Manager 5.3 software was used to conduct the metaanalysis. Results： The results showed that 17 RCTs involving 1,372 patients were included. The meta-analysis indicated that the combined use of STS and Western medicine（WM） in the treatment of UAP can obviously improve the total effective rate [risk ratio（RR）=1.31, 95% confidence interval（CI）（1.24,1.39）, P〈0.0001], and the total effective rate of electrocardiogram [RR=1.43, 95% CI（1.30,1.56）, P〈0.0001], decrease the level of CRP [mean difference（MD）=–3.06, 95%CI（–3.85, –2.27）, P〈0.00001], fibrinogen [MD=–1.03, 95% CI（–1.16, –0.89）, P〈0.00001], and whole blood high shear viscosity [MD=–0.70, 95% CI（–0.92, –0.49）, P〈0.00001]. Additionally, the occurrence of adverse drug reaction of the experimental group was significantly higher than that of the control group [RR=3.57, 95% CI（1.28, 9.94）, P〈0.05]. Conclusions： Compared with WM, the combined use of STS was more effective.

Altered Erythrocyte Membrane Calcium Binding in Hypertensive Rats and the Effects of Sodium Tanshinone Ⅱ-A Sulphonate on It

The calcium binding of erythrocyte membrane was determined in spontaneous hypertensiverats (SHR)and renovascular hypertensive rats (RVHR two-kidney, one-clip model) and the effect ofsodium tanshinone Ⅱ-A sulfonate(DS-201)on the calcium binding in SHRs was investigated. Ourresults show that the basal calcium binding was reduced in SHRs (P<0.01 vs WKY),while the maximalcalcium binding was not,but both typies calcium bindings had no significant change in RVHRs.Sodiumtanshinone Ⅱ-A sulfonate (125μ mol/L)have no effect on the calcium binding of ecythrocyte membraneof SHR in vitro.These data further support the hypothesis that there is a cell membrane abnormalitypresent in SHRs which may possibly serve as a marker genetics of in hypertension.

Tanshinone ⅡA： an overview of its biological activity and the molecular mechanism

Danshen, the rhizome of Salvia miltiorrhiza Bunge, has been used in traditional Chinese medicine （TCM） for treatment of various diseases. Tanshinone IIA （TSA） is one of the main active components of Danshen, which has multiple bioactivities. This article reviews the research progress of TSA in the treatment of cardiovascular disease, anti-inflammatory and immune, anti-tumor, liver protection, neuroprotection. It provides more ideas for the clinical application of TSA and the development of drug resistance.

丹参酮IIA磺酸钠对兔急性心梗再灌注后无复流的保护作用

目的:急性心肌梗死患者在经皮冠脉介入术后,若发生无复流则预示着更差的临床预后。研究旨在评估丹参酮IIA磺酸钠对兔急性心肌梗死后无复流发生的防治作用。方法:新西兰大白兔40只随机分成4组(n=10),即AMI对照组(I/R)、丹参酮再灌注治疗组(DS-201)、丹参酮冠脉结扎前治疗组(DS-201-pre)、假手术组(Sham),每组各10只。Sham组开胸不结扎,其余3组结扎左室缘支90 min,切断结扎线120 min建立心肌缺血再灌注模型。各组分别于结扎前5 min、结扎左心室缘支90 min、再灌注120 min时,取静脉血检测血清中肌酸激酶(CK)、肌酸激酶同工酶(CK-MB)、肿瘤坏死因子(TNF-α)的含量,最终进行病理学分析,观察HE染色后的心肌组织病理形态学变化,并评估缺血范围(LA/LVA)、无复流范围(NRA/LA)及梗死区心肌范围(MIA/LA)。结果:(1)AMI后90 min时,CK、CK-MB水平在I/R组、DS-201组和DS-201-pre 3组间差异无统计学意义(P>0.05);I/R组及DS-201组TNF-α水平均较DS-201-pre组高(P<0.05)。再灌注120 min时,DS-201-pre组及DS-201组的血清CK、CK-MB、TNF-α水平低于I/R组(P<0.01或P<0.05);DS-201-pre组与DS-201组CK、CK-MB、TNF-α水平差异无显著性(P>0.05)。(2)各组病理染色所测的冠脉结扎区心肌范围(LA)基本一致(P>0.05)。与I/R组比较,DS-201组及DS-201-pre组可以减少无复流面积(P<0.05),DS-201-pre组与DS-201组间差异无显著性(P>0.05)。(3)与I/R组比较,DS-201组及DS-201-pre组可以缩小心肌梗死面积(P<0.05),减轻心肌细胞结构损伤,DS-201-pre组与DS-201组间差异无显著性(P>0.05)。结论:丹参酮IIA磺酸钠能减轻心肌细胞结构损伤,缩小心肌梗死面积,减轻无复流的发生。其机制可能与减轻心肌炎症反应有关。

丹参酮IIA磺酸钠对血管紧张素II诱导的心肌肥大及p-ERK表达的影响

目的:观察丹参酮IIA磺酸钠(STS)对血管紧张素II(Ang II)诱导的心肌肥大及p-ERK表达的影响。方法:培养新生大鼠心肌细胞,考马斯亮蓝法测定心肌细胞蛋白含量、[3H]-亮氨酸掺入法测定蛋白合成速率作为心肌肥大指标;用West-ern-blot测定p-ERK表达。结果:STS能显著降低Ang II诱导的心肌细胞总蛋白含量、蛋白合成速率上升,同时对p-ERK表达具有剂量、时间依赖性抑制作用。结论:STS可以抑制Ang II诱导的心肌肥大,机制与抑制p-ERK表达有关。

丹参酮IIA磺酸钠对老年非ST段抬高急性冠脉综合征的疗效与安全性评价

目的观察丹参酮IIA磺酸钠注射液(STS)对老年非ST段抬高急性冠状动脉综合征(NSTE-ACS)的疗效及安全性。方法 2013年12月—2015年6月,收集老年NSTE-ACS患者,以常规治疗患者作为对照组,在常规治疗方案基础上使用STS的患者作为试验组,治疗5 d,评价心绞痛、心电图疗效和安全性。结果共计入组484例,其中对照组240例,试验组244例。试验组心绞痛总有效率优于对照组(80.74% vs 71.67%,P=0.019);心电图总有效率优于对照组(38.93%vs 13.75%,P=0.000)。随访期间2组均未观察到严重不良事件,且不良事件发生率差异无统计学意义。结论在老年NSTE-ACS患者中,STS能改善心电图异常,减少心绞痛发作次数,缓解发作症状,且具有良好的安全性。

丹参酮IIA磺酸钠注射液治疗急性脑梗死疗效分析

目的:观察丹参酮IIA磺酸钠注射液治疗急性脑梗死的临床疗效。方法先取我院60例急性脑梗死患者,随机分成两组,治疗组采用丹参酮IIA磺酸钠注射液(10 mg)50 mg静滴1次/d,疗程14 d。对照组采用西医常规方法。比较两组差异。结果两组治疗前后自身比较,差异有显著性(<0.01),两组患者治疗后神经功能缺损评分比较,治疗组比对照组有显著下降(<0.01),丹参酮组总有效率达83.2%对照组为65.3%,两组比较差异有统计学意义。结论经过试验发现丹参酮IIA磺酸钠注射液安全、可靠、无明显不良反应,具有进一步的研究价值和广阔的应用前景。

丹参酮IIA磺酸钠联合局部激素对老年突发性聋患者纯音听阈及内耳微循环的影响

目的探究丹参酮ⅡA磺酸钠(sodium tanshinoneⅡA sulfonate,STS)联合局部激素对老年突发性聋(sudden deafness,SD)患者纯音听阈及内耳微循环的影响。方法选取2020年1月~2022年1月间浙江大学医学院附属第四医院收治的老年SD患者77例,根据随机数字表法分为观察组(38例),对照组(39例)。对照组进行耳后局部激素注射,注射甲泼尼龙40 mg/次,1次/2d,连续注射7次,观察组在此基础上加用STS,40 mg/次,1次/d连续注射2周。评估治疗后不同时间的临床疗效,比较患者的血液流变学指标、耳内微循环指标、血管内皮指标,统计患者治疗期间发生的不良反应情况,评估治疗方案的安全性。结果治疗7 d、2周后,观察组治疗总有效率均高于对照组(P<0.05);治疗后,两组老年SD患者纯音听阈降低,观察组纯音听阈低于对照组(P<0.05),观察组听阈增益高于对照组(P<0.05);治疗后,两组老年SD患者血浆黏度(plasma viscosity,PV)、全血高切黏度(whole blood viscosity,WBV)水平降低,超氧化物歧化酶(superoxide dismutase,SOD)、一氧化氮(nitric oxide,NO)水平升高,基底动脉、内听动脉及小脑前下动脉管径均增加(P<0.05),观察组PV、WBV水平低于对照组,SOD、NO水平,基底动脉、内听动脉及小脑前下动脉管径均高于对照组(P<0.05);观察组、对照组患者不良反率分别为15.79%、10.26%,二者比较差异均无统计学意义(P>0.05)。结论STS联合局部激素能够提高老年SD患者的治疗疗效,改善血液流变学指标、血管内皮指标及耳内微循环指标,具有良好的安全性。

丁苯肽注射液联合丹参酮IIA磺酸钠注射液在脑梗死患者溶栓治疗中的效果探讨

目的:探讨丁苯肽注射液联合丹参酮IIA磺酸钠注射液在脑梗死患者溶栓治疗中的效果。方法:将2015年12月~2017年12月在某院神经内科治疗的116例脑梗死溶栓治疗患者随机分为两组。对照组单用爱通立溶栓治疗,在此基础上观察组使用丁苯肽注射液联合丹参酮IIA磺酸钠注射液,比较两组患者的临床疗效、神经功能及生活能力变化、神经损伤因子水平、炎性因子水平。结果:观察组治疗有效率为93.10%,明显高于对照组的77.59%(P<0.05);观察组治疗后NIHSS评分明显低于对照组,而BI指数明显高于对照组(P<0.05);观察组治疗后TNF-α、hs-CRP、IL-6水平明显低于对照组(P<0.05)。结论:丁苯肽注射液联合丹参酮IIA磺酸钠注射液在脑梗死患者溶栓治疗中的效果显著,能促进脑部受损神经功能的修复,改善脑部血液循环,抑制炎性因子对脑组织的损害,提升治疗效果。

丹参酮IIA磺酸钠辅助治疗冠心病患者的效果及其对血液流变学水平的影响

目的探究冠心病患者使用丹参酮IIA磺酸钠辅助治疗的临床效果以及其对患者血液流变学水平的影响。方法选取100例冠心病患者随机分为常规治疗组(50例,常规治疗)与辅助治疗组(50例,常规治疗+丹参酮IIA磺酸钠辅助治疗)。比较两组治疗前、后的血液流变学指标、临床效果及不良反应。结果治疗后,两组的血浆黏度、全血黏度、血小板黏附率及纤维蛋白原均降低,且辅助治疗组显著低于常规治疗组(P<0.05)。辅助治疗组的治疗总有效率显著高于常规治疗组(P<0.05)。两组的不良反应总发生率比较,差异不显著(P>0.05)。结论冠心病患者使用丹参酮IIA磺酸钠辅助治疗可改善血液流变指标,提升临床效果,并且不会明显增加不良反应。